Study of XIAP Antisense for Advanced Cancers

• Status: Terminated
• Trial end date: 2008-11-01

Summary

This study is designed to find the maximum tolerated dose, safety and toxicity profile, and to identify any dose limiting toxicities of AEG35156 administered in 2-hour infusions to patients with advanced cancers.

• Phase: Phase 1

Details

• Lead Sponsor: Aegera Therapeutics